Preference for different PrEP formulations: A cross-sectional study in a PrEP cohort in Spain

IF 3.2 3区 医学 Q2 INFECTIOUS DISEASES
HIV Medicine Pub Date : 2026-09-06 Epub Date: 2026-05-06 DOI:10.1111/hiv.70252
Alfredo Soler-Carracedo, Allison R. Webel, Luis Ramos-Ruperto, Rafael Mican-Rivera, Rocio Montejano-Sanchez, Ana Milinkovic, Stephanie A. Ruderman, Joseph P. De Santis, Jose I. Bernardino
{"title":"Preference for different PrEP formulations: A cross-sectional study in a PrEP cohort in Spain","authors":"Alfredo Soler-Carracedo,&nbsp;Allison R. Webel,&nbsp;Luis Ramos-Ruperto,&nbsp;Rafael Mican-Rivera,&nbsp;Rocio Montejano-Sanchez,&nbsp;Ana Milinkovic,&nbsp;Stephanie A. Ruderman,&nbsp;Joseph P. De Santis,&nbsp;Jose I. Bernardino","doi":"10.1111/hiv.70252","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objectives</h3>\n \n <p>To gain a better understanding of PrEP-users' preference for long-acting vs. oral PrEP formulation.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>From April 2023 to January 2024, participants who were prescribed PrEP completed an anonymous, structured, self-administered, cross-sectional survey as part of their routine PrEP care in a hospital setting in Madrid, Spain. Inclusion criteria were attendance at the clinic for PrEP care and the ability to understand the Spanish language. Eligibility was not restricted by age. A convenience sample of 200 participants was used. The ethics committee approved a waiver of written consent. Descriptive statistics and chi-square tests were used to analyse the data.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A sample of 201 participants completed the survey, of which 193 (96.5%) were male and most were 30–39 years old (48.8%). The response rate was estimated to be more than 90%. Among participants, 74.9% preferred LA-PrEP (53.9% preferred a subcutaneous (SC) injection every 6 months and 21.0% preferred an intramuscular (IM) injection every 2 months). Participants reported that LA-PrEP is more practical, indicating fewer visits to the clinic as a primary reason (67.4%). 29.4% of participants were aware of IM LA-PrEP, 10.0% of SC LA-PrEP and 10.4% were familiar with both. Respondents who selected LA-PrEP were more often under 40 years of age (<i>p</i> = 0.016) compared to those who preferred oral PrEP (73.7% vs. 61.2%, respectively). Limitations included the use of a cross-sectional design, a homogeneous sample and the use of one study location, among others.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>LA-PrEP is the preferred form of PrEP for the majority of respondents.</p>\n </section>\n </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"27 9","pages":"1530-1536"},"PeriodicalIF":3.2000,"publicationDate":"2026-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/hiv.70252","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives

To gain a better understanding of PrEP-users' preference for long-acting vs. oral PrEP formulation.

Methods

From April 2023 to January 2024, participants who were prescribed PrEP completed an anonymous, structured, self-administered, cross-sectional survey as part of their routine PrEP care in a hospital setting in Madrid, Spain. Inclusion criteria were attendance at the clinic for PrEP care and the ability to understand the Spanish language. Eligibility was not restricted by age. A convenience sample of 200 participants was used. The ethics committee approved a waiver of written consent. Descriptive statistics and chi-square tests were used to analyse the data.

Results

A sample of 201 participants completed the survey, of which 193 (96.5%) were male and most were 30–39 years old (48.8%). The response rate was estimated to be more than 90%. Among participants, 74.9% preferred LA-PrEP (53.9% preferred a subcutaneous (SC) injection every 6 months and 21.0% preferred an intramuscular (IM) injection every 2 months). Participants reported that LA-PrEP is more practical, indicating fewer visits to the clinic as a primary reason (67.4%). 29.4% of participants were aware of IM LA-PrEP, 10.0% of SC LA-PrEP and 10.4% were familiar with both. Respondents who selected LA-PrEP were more often under 40 years of age (p = 0.016) compared to those who preferred oral PrEP (73.7% vs. 61.2%, respectively). Limitations included the use of a cross-sectional design, a homogeneous sample and the use of one study location, among others.

Conclusion

LA-PrEP is the preferred form of PrEP for the majority of respondents.

对不同PrEP配方的偏好:西班牙PrEP队列的横断面研究。
目的:更好地了解PrEP使用者对长效PrEP与口服PrEP制剂的偏好。方法:从2023年4月到2024年1月,在西班牙马德里的一家医院,处方PrEP的参与者完成了一项匿名、结构化、自我管理的横断面调查,作为其常规PrEP护理的一部分。纳入标准是在诊所接受PrEP护理和理解西班牙语的能力。资格不受年龄限制。使用了200名参与者的方便样本。伦理委员会同意放弃书面同意。采用描述性统计和卡方检验对数据进行分析。结果:共201人完成调查,其中男性193人(96.5%),年龄以30-39岁居多(48.8%)。应答率估计在90%以上。在参与者中,74.9%的人选择LA-PrEP(53.9%的人选择每6个月皮下注射(SC), 21.0%的人选择每2个月肌肉注射(IM))。参与者报告LA-PrEP更实用,表明较少的诊所就诊是主要原因(67.4%)。29.4%的参与者知道IM LA-PrEP, 10.0%的参与者知道SC LA-PrEP, 10.4%的参与者对两者都熟悉。选择LA-PrEP的受访者年龄在40岁以下的比例高于口服PrEP(分别为73.7%和61.2%)(p = 0.016)。局限性包括使用横断面设计、同质样本和使用一个研究地点等。结论:LA-PrEP是大多数受访者首选的PrEP形式。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
HIV Medicine
HIV Medicine 医学-传染病学
CiteScore
5.10
自引率
10.00%
发文量
167
审稿时长
6-12 weeks
期刊介绍: HIV Medicine aims to provide an alternative outlet for publication of international research papers in the field of HIV Medicine, embracing clinical, pharmocological, epidemiological, ethical, preclinical and in vitro studies. In addition, the journal will commission reviews and other feature articles. It will focus on evidence-based medicine as the mainstay of successful management of HIV and AIDS. The journal is specifically aimed at researchers and clinicians with responsibility for treating HIV seropositive patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书